$EIKN News

Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate

Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Cantor Fitzgerald Initiates Coverage On Eikon Therapeutics with Overweight Rating

JP Morgan Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $29

This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

B of A Securities Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $34

Mizuho Initiates Coverage On Eikon Therapeutics with Outperform Rating, Announces Price Target of $26

Morgan Stanley Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $32

Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls

Wedbush Initiates Coverage On Eikon Therapeutics with Underperform Rating, Announces Price Target of $7

Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead

U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years

Eikon Therapeutics IPO Opens For Trade At $17.05/Share; IPO Priced At $18/Share

Eikon Therapeutics IPO Opens For Trade At $17.05/Share; IPO Priced At $18/Share

Eikon Therapeutics IPO Indicating $17.05/Share On 1.21M Shares; IPO Priced At $18

Eikon Therapeutics IPO Indicating $17.15/Share On 925K Shares; IPO Priced At $18

Eikon Therapeutics IPO Indicating $17.75/Share On 360K Shares; IPO Priced At $18